343 related articles for article (PubMed ID: 32992737)
1. The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients.
Tomela K; Pietrzak B; Schmidt M; Mackiewicz A
Life (Basel); 2020 Sep; 10(10):. PubMed ID: 32992737
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Jessurun CAC; Vos JAM; Limpens J; Luiten RM
Front Oncol; 2017; 7():233. PubMed ID: 29034210
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
[TBL] [Abstract][Full Text] [Related]
5. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
6. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
7. The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman DD; Hurd D; Davar D
Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?
Kuske M; Haist M; Jung T; Grabbe S; Bros M
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406483
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.
Chat V; Ferguson R; Simpson D; Kazlow E; Lax R; Moran U; Pavlick A; Frederick D; Boland G; Sullivan R; Ribas A; Flaherty K; Osman I; Weber J; Kirchhoff T
Cancer Immunol Immunother; 2019 Jun; 68(6):897-905. PubMed ID: 30863922
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
11. The Era of Checkpoint Inhibition: Lessons Learned from Melanoma.
Paschen A; Schadendorf D
Recent Results Cancer Res; 2020; 214():169-187. PubMed ID: 31473853
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
Tandon P; Bourassa-Blanchette S; Bishay K; Parlow S; Laurie SA; McCurdy JD
J Immunother; 2018 Apr; 41(3):101-108. PubMed ID: 29401166
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
15. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
Yi M; Jiao D; Qin S; Chu Q; Wu K; Li A
Mol Cancer; 2019 Mar; 18(1):60. PubMed ID: 30925919
[TBL] [Abstract][Full Text] [Related]
17. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
18. [Not Available].
Frelau A; Pracht M; Le Sourd S; Lespagnol A; Corre R; Ménard C; Tarte K; Mosser J; Edeline J
Bull Cancer; 2018 Dec; 105 Suppl 1():S80-S91. PubMed ID: 30595202
[TBL] [Abstract][Full Text] [Related]
19. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
20. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
